Wireless Eye Implant Restores Vision for Macular Degeneration Patients

Clinical trial finds 81% of patients regained meaningful vision after receiving tiny retinal implant.

Mar. 13, 2026 at 7:00am

Got story updates? Submit your updates here. ›

A new wireless retinal implant smaller than a thumbnail has restored meaningful central vision in 81% of patients with advanced age-related macular degeneration (AMD) in a major clinical trial. The implant, developed by Science Corporation, replaces damaged photoreceptors and allows users to adjust settings like zoom and contrast to assist with tasks like reading, recognizing faces, and navigating rooms.

Why it matters

Geographic atrophy, the advanced form of AMD, is the leading cause of permanent blindness in older adults. Unlike earlier stages of AMD, there are currently no approved treatments that can restore vision once it's been lost. The successful results of this large clinical trial provide hope for those living with this debilitating condition.

The details

The international PRIMAvera trial followed 38 patients aged 60 and older across 17 medical centers in Europe. After 12 months, participants had gained an average of 25 letters on a standard eye chart, with one patient gaining 59 letters. More than 80% of patients were able to read letters, words, and even pages in a book. The implant works by capturing images through a camera in specialized glasses and transmitting the signal via near-infrared light to the implant, which then converts it into electrical pulses to stimulate the retina's surviving cells.

  • The PRIMAvera trial results were published in March 2026.
  • The first U.S. implantation of the PRIMA device was performed at UPMC in 2020.

The players

Science Corporation

The company that developed the wireless retinal implant technology used in the trial.

Dr. José-Alain Sahel

Director of the UPMC Vision Institute and senior author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“More than 80 percent of the patients were able to read letters and words, and some reading pages in a book.”

— Dr. José-Alain Sahel, Director, UPMC Vision Institute (New England Journal of Medicine)

What’s next

Science Corporation has submitted approval applications for the PRIMA device in both Europe and the United States. Regulatory timelines vary, but the successful PRIMAvera trial results give the research team a strong case for approval.

The takeaway

This wireless retinal implant represents a major breakthrough in restoring vision for those living with the advanced form of age-related macular degeneration, a leading cause of permanent blindness. If approved, it could dramatically improve the quality of life for millions of older adults worldwide.